This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Goffinet, C.
Right arrow Articles by Keppler, O. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goffinet, C.
Right arrow Articles by Keppler, O. T.

 Previous Article  |  Next Article 

Journal of Virology, August 2009, p. 7706-7717, Vol. 83, No. 15
0022-538X/09/$08.00+0     doi:10.1128/JVI.00683-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo {triangledown}

Christine Goffinet,1 Ina Allespach,1 Lena Oberbremer,1 Pamela L. Golden,2 Scott A. Foster,2 Brian A. Johns,2 Jason G. Weatherhead,2 Steven J. Novick,2 Karen E. Chiswell,2 Edward P. Garvey,2* and Oliver T. Keppler1*

Department of Virology, University of Heidelberg, Heidelberg, Germany,1 GlaxoSmithKline, Infectious Disease CEDD, Research Triangle Park, North Carolina2

Received 2 April 2009/ Accepted 11 May 2009

Clinical trials of the first approved integrase inhibitor (INI), raltegravir, have demonstrated a drop in the human immunodeficiency virus type 1 (HIV-1) RNA loads of infected patients that was unexpectedly more rapid than that with a potent reverse transcriptase inhibitor, and apparently dose independent. These clinical outcomes are not understood. In tissue culture, although their inhibition of integration is well documented, the effects of INIs on levels of unintegrated HIV-1 cDNAs have been variable. Furthermore, there has been no report to date on an INI's effect on these episomal species in vivo. Here, we show that prophylactic treatment of transgenic rats with the strand transfer INI GSK501015 reduced levels of viral integrants in the spleen by up to 99.7%. Episomal two-long-terminal-repeat (LTR) circles accumulated up to sevenfold in this secondary lymphoid organ, and this inversely correlated with the impact on the proviral burden. Contrasting raltegravir's dose-ranging study with HIV patients, titration of GSK501015 in HIV-infected animals demonstrated dependence of the INI's antiviral effect on its serum concentration. Furthermore, the in vivo 50% effective concentration calculated from these data best matched GSK501015's in vitro potency when serum protein binding was accounted for. Collectively, this study demonstrates a titratable, antipodal impact of an INI on integrated and episomal HIV-1 cDNAs in vivo. Based on these findings and known biological characteristics of viral episomes, we discuss how integrase inhibition may result in additional indirect antiviral effects that contribute to more rapid HIV-1 decay in HIV/AIDS patients.

* Corresponding author. Mailing address for E. Garvey: GlaxoSmithKline, Infectious Disease CEDD, Research Triangle Park, NC. Phone and fax: (919) 357-2500. E-mail: epgarvey{at}bellsouth.net. Mailing address for O. T. Keppler: Department of Virology, University of Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany. Phone: 49-6221-565007. Fax: 49-6221-565003. E-mail: oliver_keppler{at}med.uni-heidelberg.de

{triangledown} Published ahead of print on 20 May 2009.

Journal of Virology, August 2009, p. 7706-7717, Vol. 83, No. 15
0022-538X/09/$08.00+0     doi:10.1128/JVI.00683-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»